65,437 trials
Hepatitis C Infection
Primary: Percentage of Participants With Extended Rapid Virologic Response (eRVR) — 12.5; 66.7; 62.5; 62.5 percentage of participants
Malocclusion
Primary: Rate of Orthodontic Anterior Alignment in Millimetres Per Week (mm/wk) by Means of Little's Irregularity Index (LII) for OrthoPulse™ and Non-OrthoPulse™ Treated…
We Will Focus on Assessing the Clinical Performance of the BiliCare Device
Primary: BiliCare TcB Result Compared to TSB Result — 8.0; 7.3 mg/dL
We Will Focus on Assessing the Clinical Performance of the BiliCare Device
Primary: BiliCare TcB Result Compared to TSB Result — 8.46; 7.93; 7.83 mg/dL
Graft vs. Host Disease
Primary: T Regulatory Cell (Treg)/Total Cluster of Differentiation 4 (CD4)+ Ratio — 13; 11 ratio
Postoperative Pain · Shoulder Pain
Primary: Patient Reported Pain on Day 0 — 30.2; 24.2 Visual Analog Score (0-100)
Deglutition Disorders
Primary: Mortality Calculated From Outcome Section From DPC Database at 90 Days — 359; 287 Participants
Hematopoietic/Lymphoid Cancer
Primary: Behavioral - Stress Level as Measured by the Perceived Stress Scale (PSS) — 23.5; 22.7; 21.6; 22.0 units on a scale — p=0.020
Chronic Hepatitis C
Primary: Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died — 0; 0; 0; 0 participants
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Objective Response Rate — 3 percentage of patients with response
Neonatal Infection
Primary: The Number (Rate) of Patients With Acute Respiratory Infections — 3; 14 participants — p=0.05
Chronic Migraine, Headaches
Primary: Change From Baseline in the Number of Headache Days — 19.08; 6.25 Days
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001
Renal Failure
Primary: Composite Endpoint for Efficacy Failure Within 12 Months of Randomization: Death, Graft Failure, Biopsy-proven Acute Rejection or Loss to Follow-up. — 2; 1; 0; 0…
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 88; 71 percentage of participants